ArticleBMC microbiology2025
Study on the heteroresistance of carbapenem-resistant Klebsiella pneumoniae to Tigecycline and Polymyxin B and antibacterial activity of combined drugs in vitro.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance is a global concern. Tigecycline (TGC) and polymyxin B (PMB) constitute some of the last treatment options remaining for carbapenem-resistant Klebsiella pneumoniae (CRKP). However, heteroresistance to these two drugs has rarely been reported. In this study, we investigated the prevalence of heteroresistance to TGC and PMB among clinically isolated CRKP strains, and assessed the synergistic activity of TGC plus PMB, TGC plus imipenem (IPM), and PMB plus IPM against heteroresistant CRKP.
methodsA total of 90 nonduplicated CRKP clinical isolates were collected from Tianjin Medical University General Hospital, China,from January 2022 to October 2022. PCR was used to detect the resistance genes. Population analysis profile (PAP) was performed to determine the existence of heteroresistance. Checkerboard assay was carried out on ten randomly selected dual-heteroresistant CRKP strains. Additionally, MIC
resultsAmong them, 48 (55.2%) of the 87 TGC-susceptible and TGC-immediate isolates exhibited heteroresistance phenotypes, and 61 (70.9%) of the 86 PMB-susceptible isolates showed heteroresistance phenotypes. Thirty-two isolates (35.6%) were heteroresistant to TGC and PMB simultaneously. PCR results showed that 96.7% (87/90) not only carried carbapenemase genes, but also co-harbored extended-spectrum β-lactamases (ESBLs) genes. Single time-kill curves demonstrated that PMB monotherapy could rapidly eradicate non-heteroresistant strains within 8 h. Conversely, in heteroresistant strains, there was a sharp reduction in cells numbers initially but ensuing a prompt rebound. Intriguingly, further heteroresistance screening decoded the occurrence of heteroresistance phenomenon. Importantly, Checkerboard assay exhibited TGC combined with PMB exert relatively better effect to overcome dual heteroresistance compared with the other two regimes, with MIC
conclusionThis study provides valuable insights and theoretical support for the clinical therapy of relevant heteroresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.